Search
Filter Results
Displaying 41–50 of 835 for “retinal diseases”
-
Feb 7, 2020
Genetic Testing for Inherited Retinal Diseases through the Foundation’s Open Access Program
The benefits of genetic testing for IRD patients, how to participate in the Foundation’s Open Access program, and what to expect from the genetic testing process.
-
May 30, 2018
French Gene Therapy Company Advancing Three Programs for Retinal Diseases
Horama’s gene therapies are injections of healthy copies of a gene underneath the retina to compensate for the defective gene.
-
Sep 28, 2021
RD Fund Launches Opus Genetics to Advance Gene Therapies for Inherited Retinal Diseases
First two programs are for Leber congenital amaurosis: LCA5-lebercillin and LCA13-RDH12
-
May 2, 2018
ARVO 2018: Dr. Steve Rose Reports on CRISPR/Cas9 for Inherited Retinal Diseases
FFB’s own Dr. Steve Rose, chief scientific officer, reviews our commitment to funding and exploring CRISPR/Cas9 gene editing for inherited retinal disease.
-
Apr 1, 2022
Drug for Alcohol Abuse May Restore Vision for People with Retinal Diseases
The drug holds promise for enabling retinal-disease patients to get more vision from remaining photoreceptors
-
Access to Retinal Disease Eye Tissue
For over 25 years the Foundation Fighting Blindness has supported the collection of eye globes from donors diagnosed with an inherited retinal degeneration, which is housed at the Cleveland Clinic Cole Eye Institute. The collection of over 900 eye globes are freely available for retina research.
-
PRPH2 and Associated Retinal Diseases (PARD) Science Award
Overview and application instructions for the PRPH2 and Associated Retinal Diseases (PARD) Science Award
-
Release Date: June 5, 2020 Expiration Date: May 29, 2023
This activity offers CE credit for: a. Physicians (CME) b. Optometrists (COPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™.
-
May 27, 2020
Abfero Targeting Excess Iron to Treat AMD, Other Retinal Diseases
An intriguing link between excess body iron and retinal degeneration is being explored by Abfero Pharmaceuticals, a young biotech based in Boston and Oxford, UK.